GREM1 and cancer: Given the discussions above, the potential of these neutralizing GREM1 antibodies to inhibit GREM1 signaling not only in cancer cells, but also in CSCs (thereby restoring BMP-induced CSC differentiation and other signaling), is a tantalizing prospect that could reduce the CSC population in tumors and improve patient outcomes.